Smaller biotechs see new mechanisms of action as future of obesity treatments
Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...
pharmaphorum1d
Scholar Rock preps filings after SMA antibody clears trial
Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...
Seeking Alpha14d
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock has done well to advance its anti-myostatin ... who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would ...
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases ...
Business Wire4d
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Hosted on MSN2mon
Biohaven’s SMA Trial Miss Bolsters Scholar Rock Stock: Analysts Give Verdicts, Retail Watches Closely
Shares of Biohaven Pharmaceutical Holding Company ($BHVN) rose 2% on Monday afternoon, reversing early losses, while rival Scholar Rock Holding Corp. ($SRRK) surged ...
Scholar Rock’s (SRRK) “Outperform” Rating Reiterated at Wedbush
Wedbush restated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $47.00 target price on ...
Benzinga.com4mon
Scholar Rock Holding (NASDAQ:SRRK) Stock Quotes, Forecast and News Summary
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global ...
Business Wire16d
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Yahoo Finance27d
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., January 17, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...
Morningstar16d
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
Biomedicines and Acceleron Pharma. She joins Scholar Rock’s Executive Team, reporting directly to Jay Backstrom, M.D., MPH, President and Chief Executive Officer. As the Company transitions to a ...
Nasdaq16d
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
Ted Myles, COO & CFO at Scholar Rock, will remain with the Company through mid-March, and then serve as a Senior Advisor for six months, during the leadership transition. “I am delighted to have ...